99 related articles for article (PubMed ID: 30368994)
1. Mechanism-based inactivation of cytochrome P450 2D6 by chelidonine.
Liu Y; Cui T; Peng Y; Ji M; Zheng J
J Biochem Mol Toxicol; 2019 Feb; 33(2):e22251. PubMed ID: 30368994
[TBL] [Abstract][Full Text] [Related]
2. Nitidine Chloride Is a Mechanism-Based Inactivator of CYP2D6.
Mao X; Hu Z; Wang Q; Zhang N; Zhou S; Peng Y; Zheng J
Drug Metab Dispos; 2018 Aug; 46(8):1137-1145. PubMed ID: 29773554
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based inactivation of cytochrome P450 2D6 by Notopterol.
Fu Y; Tian X; Han L; Li Y; Peng Y; Zheng J
Chem Biol Interact; 2020 May; 322():109053. PubMed ID: 32198085
[TBL] [Abstract][Full Text] [Related]
4. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
[TBL] [Abstract][Full Text] [Related]
5. Oxypeucedanin is a Mechanism-based Inactivator of CYP2B6 and CYP2D6.
Zhang K; Li Y; Fu Y; Cui T; Wang Q; Mao X; Peng Y; Zheng J
Curr Drug Metab; 2021; 22(11):882-892. PubMed ID: 34191696
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo studies of the metabolic activation of chelidonine.
Liu Y; Peng Y; Zhang Z; Guo X; Ji M; Zheng J
Chem Biol Interact; 2019 Aug; 308():155-163. PubMed ID: 31102647
[TBL] [Abstract][Full Text] [Related]
7. Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates cytochrome P450 2D6 by protein adduction.
Nagy LD; Mocny CS; Diffenderfer LE; Hsi DJ; Butler BF; Arthur EJ; Fletke KJ; Palamanda JR; Nomeir AA; Furge LL
Drug Metab Dispos; 2011 Jun; 39(6):974-83. PubMed ID: 21422192
[TBL] [Abstract][Full Text] [Related]
8. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6.
Niwa T; Shizuku M; Yamano K
Arch Biochem Biophys; 2017 Apr; 620():23-27. PubMed ID: 28347660
[TBL] [Abstract][Full Text] [Related]
9. Constituents of Indonesian medicinal plant Averrhoa bilimbi and their cytochrome P450 3A4 and 2D6 inhibitory activities.
Auw L; Subehan ; Sukrasno ; Kadota S; Tezuka Y
Nat Prod Commun; 2015 Jan; 10(1):57-62. PubMed ID: 25920220
[TBL] [Abstract][Full Text] [Related]
10. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
11. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
Wang A; Stout CD; Zhang Q; Johnson EF
J Biol Chem; 2015 Feb; 290(8):5092-5104. PubMed ID: 25555909
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus.
Usia T; Watabe T; Kadota S; Tezuka Y
Biol Pharm Bull; 2005 Jun; 28(6):1021-4. PubMed ID: 15930738
[TBL] [Abstract][Full Text] [Related]
13. Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6.
Martiny VY; Carbonell P; Chevillard F; Moroy G; Nicot AB; Vayer P; Villoutreix BO; Miteva MA
Bioinformatics; 2015 Dec; 31(24):3930-7. PubMed ID: 26315915
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-Based Inactivation of CYP2D6 by Phellopterin and Related Drug-Drug Interaction with Metoprolol.
Cheng Z; He Y; Chen Y; Zhao G; Liu Y; Zhang J; Li X; Ran G; Zhang Q; Peng Y; Li W; Zheng J
J Agric Food Chem; 2024 Jan; 72(3):1745-1755. PubMed ID: 38214270
[TBL] [Abstract][Full Text] [Related]
16. Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6.
Akiyoshi T; Ishiuchi M; Imaoka A; Ohtani H
Drug Metab Pharmacokinet; 2015 Aug; 30(4):321-4. PubMed ID: 26195224
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction.
Hutzler JM; Steenwyk RC; Smith EB; Walker GS; Wienkers LC
Chem Res Toxicol; 2004 Feb; 17(2):174-84. PubMed ID: 14967005
[TBL] [Abstract][Full Text] [Related]
18. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
19. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors.
Jensen BF; Vind C; Padkjaer SB; Brockhoff PB; Refsgaard HH
J Med Chem; 2007 Feb; 50(3):501-11. PubMed ID: 17266202
[TBL] [Abstract][Full Text] [Related]
20. The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation.
Lin XX; Lian GH; Xu Y; Zhao Q; Xiao J; Peng SF; Xiao MF; Ouyang DS; Tan ZR; Wang YC; Peng JB; Zhang W; Chen Y
Xenobiotica; 2018 Oct; 48(10):999-1005. PubMed ID: 29027845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
